KINASE INHIBITORS

Home Kinase Inhibitors News & Literature Highlights

Ventricular Tachycardia Storm in a Patient Treated With Ibrutinib for Waldenstrom Macroglobulinemia

Take a deep dive into the treatment course of a 68-year-old male patient with Waldenstrom macroglobulinemia who experienced atrial fibrillation and multiple episodes of polymorphic ventricular tachycardia after beginning treatment with ibrutinib.

JACC: CardioOncology

Class Categories

Immune Checkpoint Inhibitors

Kinase Inhibitors

HER2-Targeted Therapies

Novel Immunotherapies (CAR-T, BiTE)

CARDIO-ONCOLOGY BASICS

What is Cardio-Oncology?

Link Between Cancer, Treatment, and Heart Disease

Cardio-Oncology Standards of Care

CV Evaluation of Patients Before and During Cancer Therapy

Cancer Treatment–Related Cardiotoxicity

Breast Cancer Drugs and Cardiotoxicity

Cardio-Oncology Basics: Conclusions

Meet the Faculty

Resources

General Cardio-Oncology The Cancer Patient and Cardiology

General Cardio-Oncology The Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio‐Oncology Council of the European Society of Cardiology (ESC)

General Cardio-Oncology Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools From the Cardio-Oncology Study Group of the Heart Failure Association of the European Society

General Cardio-Oncology NCCN Clinical Practice Guidelines in Oncology: Survivorship Version 2.2020

General Cardio-Oncology Cardiovascular and Cancer Risk: The Role of Cardio-Oncology

Videos

Kinase Inhibitors Managing Ibrutinib-Associated Cardiotoxicity in CLL: A Case Study

Kinase Inhibitors Managing Nilotinib-Associated Cardiotoxicity in CML: A Case Study

Kinase Inhibitors Kinase Inhibitors and Cardiotoxicity: The Pharmacist Perpsective

General Cardio-Oncology Welcome Message from the Program Chair